SGS partnership helps clients to beat pharmaceutical counterfeiting
Partnership will provide SGS clients with a unique additional analytical service that uses cutting-edge technology to verify product authenticity, process authenticity and product/process infringement.
SGS has entered into a partnership with Nature’s Fingerprint, a Connecticut-based division of Molecular Isotope Technologies, specializing in product and process authentication via natural tracers, to mitigate identity theft of bio/pharmaceutical products and the patented synthetic pathways by which they are produced.
Counterfeiting of products and infringement of patented processes are multi-billion dollar problems for the bio/pharmaceutical industry and their global supply chain. This partnership will enable SGS to provide its clients with a unique additional analytical service that uses cutting-edge technology to verify product authenticity, process authenticity and product/process infringement.
Nature’s Fingerprint’s technology relies on the precise determination of stable isotope ratios (naturally existing tracers) obtained by combustion and mass spectrometric analyses of either bulk phases or specific compounds. The expertise of Nature’s Fingerprint’s scientific team is in the innovative application of these methodologies to bio/pharmaceutical products and processes, ranging from process authentication to raw material provenance identification and manufacturing process discrimination.
“Through this partnership, SGS now has the capability to enhance its analytical consulting and analytical service offering, especially with regard to comparability or biosimilarity studies,” commented Mark Rogers, Global Technical Director, Life Sciences. “SGS’s unrivaled experience in this field will now extend to the selection and categorization of reference material lots and manufacturing process profiling.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.